Final week, Johnson & Johnson (J&J) reported gross sales of €23.7bn ($24bn) for Q2 2022, up 3% on the earlier yr, together with first half (H1) gross sales of €46.6bn ($47.4bn), up 4 %. Web earnings or revenue throughout the group, nonetheless, declined by 23.3% to €4.75bn ($4.8bn) in Q2. Adjusted web earnings for the quarter, excluding after-tax intangible asset amortization expense and particular gadgets, sat at €6.79bn ($6.9bn), up 4.3%.

Gross sales in J&J’s shopper well being division – containing its oral care and pores and skin well being portfolio, quickly to be carved out right into a standalone enterprise– – have been down 1.3% for Q2 at €3.74bn ($3.8bn) and down 1.4% for H1 at €7.27 bn ($7.39bn). Jessica Moore, VP of investor relations at Johnson & Johnson, stated outcomes on this division had been “negatively impacted by regional COVID-19 mobility restrictions”,​ significantly the pores and skin well being and sweetness franchise.

Magnificence and skincare dealing with macro headwinds

Joseph Wolk, govt VP and CFO at Johnson & Johnson, instructed analysts the corporate’s magnificence and pores and skin well being portfolios have been additionally significantly uncovered to industry-wide “headwind macro”​similar to provide constraints and inflationary pressures round enter prices. Although Wolk famous the previous had already began to ease in Q2.

Responding to an analyst’s query, he stated J&J’s pores and skin well being and sweetness divisions have been primed to be “a lot stronger”​within the second half (H2) of 2022.

“We all know that point-of-sale demand continues to be robust for merchandise like Aveeno and Neutrogena, and we simply did not have sufficient on the shelf within the first half. We do anticipate that we’ll have extra availability on the shelf within the second half of this yr,”he stated.